In the past 5 year, the MSKCC investigators have performed clinical trials involving a variety of signal transduction agents as well as novel agents of unusual mechanism. The center has extensive experience in the conduct of Phase I studies related to small molecules, monoclonal antibodies and vaccines. This research proposes to develop new information relevant to the treatment of cancer by conducting Phase I studies of new anticancer drugs and pharmacologic modulatory regimens which attempt to enhance the therapeutic efficacy of new drugs. Concurrent with the clinical studies, the research will evaluate the distribution and metabolism of the study drugs and examine their biological effects at the clinical biochemical and molecular level.
The Specific Aims will be to perform Phase I clinical trials with agents from the following classes: 1) Modulators of epigenetic regulation of gene expression (putative differentiation therapy) such as retinoids, histone deacetylase inhibitors and demethylating agents; 2) Signal Transduction Targets such as protein kinase C, AKT, HER2 and cell cycle dependent kinases; 3) Phase I Testing of Tumor (Histology Specific) Therapies such as agents appropriate for a single tumor type like prostate cancer; and 4) Immunologic Therapy. The planned clinical trials are to be awarded by the CTEP staff in response to LOI's. We hope to take advantage of the laboratory insights provided by laboratory and clinical investigators at the MSKCC to provide new hypotheses for Phase I clinical testing. Correlative sciences including pharmacokinetics, gene expression, protein expression, functional imaging and assessment of endpoints in biopsy material are expected to be a major part of the studies to be done. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA069856-11
Application #
6881337
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (O1))
Program Officer
Jensen, Leeann T
Project Start
1995-05-16
Project End
2008-02-29
Budget Start
2005-08-30
Budget End
2006-02-28
Support Year
11
Fiscal Year
2005
Total Cost
$407,039
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Xu, Ran; Shimizu, Fumiko; Hovinga, Koos et al. (2016) Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clin Cancer Res 22:4786-4796
Iasonos, Alexia; O'Quigley, John (2014) Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol 32:2505-11
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
Goldlust, S A; Hsu, M; Lassman, A B et al. (2012) Seizure prophylaxis and melanoma brain metastases. J Neurooncol 108:109-14
Iasonos, Alexia; Gounder, Mrinal; Spriggs, David R et al. (2012) The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clin Cancer Res 18:5179-87
Iyer, Gopa; Morris, Michael J; Rathkopf, Dana et al. (2012) A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol 69:1089-97
Paik, Paul K; Rudin, Charles M; Pietanza, Maria C et al. (2011) A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 74:481-5
Daher, May; Lacouture, Mario E; Rathkopf, Dana et al. (2011) Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. J Clin Oncol 29:e638-40
Paik, Paul K; Rudin, Charles M; Brown, Andrew et al. (2010) A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 66:1079-85
Janjigian, Yelena Y; Lee, Wooin; Kris, Mark G et al. (2010) A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol 65:833-8

Showing the most recent 10 out of 22 publications